论文部分内容阅读
目的:分析哮喘合并变应性鼻炎行酮替芬联合舒利迭治疗的疗效。方法:回顾性分析2010年5月至2015年5月本院诊治的110例哮喘合并变应性鼻炎患者临床资料,按照不同治疗方式分为两组(各55例),对照组予以沙丁胺醇+布地奈德治疗,研究组予酮替芬+舒利迭治疗,观察并对比两组具体治疗情况。结果:两组治疗后ACT、SFAR、MOS-HIV及主要肺功能指标均较治疗前改善,其中研究组改善幅度更显著,且优于对照组(P<0.05);研究组不良反应总发生率9.09%显著低于对照组20.00%,具统计学意义(P<0.05)。结论:哮喘合并变应性鼻炎行酮替芬联合舒利迭治疗安全有效,具有临床实际应用价值。
Objective: To analyze the curative effect of ketotifen and seretide in patients with asthma and allergic rhinitis. Methods: The clinical data of 110 asthmatic patients with allergic rhinitis diagnosed and treated in our hospital from May 2010 to May 2015 were retrospectively analyzed. The patients were divided into two groups (55 cases each) according to different treatment methods. The control group was treated with salbutamol + budesonide Ned treatment, the study group to ketotifen + seretide treatment, observed and compared two groups of specific treatment. Results: After treatment, the ACT, SFAR, MOS-HIV and the main pulmonary function indexes of both groups improved compared with those before treatment, and the improvement rate of the study group was more significant than that of the control group (P <0.05). The total adverse reaction rate 9.09% was significantly lower than the control group 20.00%, with statistical significance (P <0.05). Conclusions: The combination of ketotifen and seretide for asthma with allergic rhinitis is safe and effective, which has clinical value.